Christopher Cannon: Clopidogrel Monotherapy is Superior to Aspirin Monotherapy for MACCE Prevention
Christopher Cannon, Cardiologist at Brigham and Women’s Hospital, Editor-in-Chief of Harvard Heart Letter, posted on LinkedIn:
”New meta-analysis: “clopidogrel monotherapy is superior to aspirin monotherapy for MACCE prevention with no increase in the risk of bleeding.” The CAPRIE trial had it right 20 years ago.
I have been shifting more and more of my patients to long-term clopidogrel in place of ASA.”
Read the full article here.
Title: Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis
Authors: Marco Valgimigli, Ki Hong Choi, Daniele Giacoppo, Felice Gragnano, Takeshi Kimura, Hirotoshi Watanabe, Hyo-Soo Kim, Jeehoon Kang, Kyung Woo Park, Alf-Åge Pettersen, Mark Woodward, Deepak L Bhatt, Paolo Calabrò, Dominick J Angiolillo, Roxana Mehran, Young Bin Song, Joo-Yong Hahn
Stay updated with Hemostasis Today.
-
Feb 21, 2026, 15:58Addressing Underdiagnosis and Care Inequities in Women and Girls with Bleeding Disorders – WFH
-
Feb 21, 2026, 15:49Sheharyar Raza: The Leaky Pipeline of AI and Machine Learning in Transfusion Medicine
-
Feb 21, 2026, 15:21Joanna Sadowska: Watching a Stem Cell Divide Reveals Life’s Blueprint
-
Feb 21, 2026, 14:43Gashaw Arega: Demonstrating Impact Through Blood Donation for Childhood Cancer
-
Feb 21, 2026, 14:42Travel Tips for Attending WFH 2026 World Congress in Kuala Lumpur
-
Feb 21, 2026, 13:56Tagreed Alkaltham: Transfusion Misidentification – When Identity Errors Become Fatal
-
Feb 21, 2026, 13:46Timothy Stalker: Differences Between Arterial and Venous Hemostasis
-
Feb 21, 2026, 13:36Augustina Isioma Ikusemoro: Strengthening Awareness and Prevention on World Anaemia Awareness Day
-
Feb 21, 2026, 13:20Mary Cushman: Novel Proteins Shed Light on the Mechanisms of VTE